Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Recent evidence indicates that ALC regulates processes that go beyond its classical role in energy metabolism
This chronic condition results from a combination of factors, including genetic predisposition, poor dietary habits, sedentary lifestyles, and environmental influences
Structures of leukotriene biosynthetic enzymes and development of new therapeutics
Key findings from this 48-week, dose-ranging study of 338 adults with obesity: Participants receiving the highest dose (12 mg weekly) lost an average of 24.2% of their body weight in 48 weeks At the 12 mg dose, 100% of participants lost at least 5% of their body weight Approximately 83% of participants on the highest dose lost 15% or more of body weight The weight loss trajectory had not plateaued at 48 weeks, suggesting even greater weight loss with continued treatment To put these numbers in context, here is how retatrutides Phase 2 data compares to the landmark trials of existing medications: The fact that retatrutide achieved the highest percentage of weight loss in the shortest timeframe is what has researchers and patients so excited
US$ 25.61
US$ 28.92
US$ 27.92
US$ 28.86
US$ 21.64
US$ 27.02
US$ 24.31
US$ 20.23
